MARKET

IBIO

IBIO

IBIO
AMEX

Real-time Quotes | Nasdaq Last Sale

2.190
-0.080
-3.52%
Opening 12:38 09/23 EDT
OPEN
2.180
PREV CLOSE
2.270
HIGH
2.250
LOW
2.140
VOLUME
4.24M
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
0.0500
MARKET CAP
381.97M
P/E (TTM)
-1.8512
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Global vaccine plan gains momentum, U.S. not on board
An $18B initiative to ensure any future vaccine against COVID-19 is fairly shared throughout the world has secured the backing of 156 countries and territories, representing about 64% of the
Seekingalpha · 1d ago
IBio is Still Sitting in the Starting Gates of the Vaccine Race
IBio (NYSEAMERICAN:IBIO) shares have continued their pattern of volatility with recent news. The pandemic grinds on, and the world's economies continue to look for positive signs. Thus, news regarding vaccine laggards -- including iBio -- becomes a renewed source of investor hope. Trading spikes.
InvestorPlace · 1d ago
iBio Is a Wishful Thinkers Coronavirus Vaccine Bet
iBio (NYSEAMERICAN:IBIO) is one of many biotechs that benefited from the hype surrounding a potential novel coronavirus vaccine in February. During the first five months of the year, IBIO stock shot up a massive 333.73%. However, the stock is up a relatively modest 73% since May.Source: Shutterstock
InvestorPlace · 4d ago
Small stocks may thrive in 2021 � no matter who wins the election
CNN.com · 5d ago
iBio To Advance Coronavirus LicKM-Subunit Vaccine Candidate, IBIO-201
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201 – IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies –   – iBio Plans to Continue Development of
Benzinga · 09/09 12:46
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies – – iBio Plans to Continue Development of IBIO-200, its Virus-Like Particle Platform – NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics
GlobeNewswire · 09/09 12:45
Is CureVac a Buy on the Pullback? It Depends
Pandemic vaccine plays have cooled off as of late. And that includes recent IPO CureVac (NASDAQ:CVAC). After going public last month at $16 per share, CureVac stock soared to prices topping $85 per share. But, in the past few weeks, as investors reassess upside potential, shares have pulled back, and
InvestorPlace · 09/03 20:29
AstraZeneca starts U.S. final-stage trial of COVID-19 Vaccine
AstraZeneca (NYSE:AZN) has expanded development of its COVID-19 vaccine AZD1222 into Phase III clinical trial in the U.S. to assess its safety, efficacy an
Seeking Alpha - Article · 09/01 06:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of IBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.19%
Shares Outstanding: 174.42M
TypeInstitutionsShares
Increased
4
14.06K
New
2
19.83K
Decreased
3
6.98K
Sold Out
1
250
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.45%
Pharmaceuticals & Medical Research
+0.06%
Key Executives
Chairman/Chief Executive Officer/Director
Thomas Isett
President
Robert Erwin
Director
Robert Kay
Independent Director
Glenn Chang
Independent Director
Seymour Flug
Independent Director
James Hill
Independent Director
John McKey
Independent Director
Philip Russell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.